Table 4 Descriptive statistics of PILRA R78G-A carriers and non-carriers stratified by case–control status.
From: PILRA polymorphism modifies the effect of APOE4 and GM17 on Alzheimer’s disease risk
AD cases | Controls | |||||
|---|---|---|---|---|---|---|
PILRA A/A n = 21 | PILRA A/G n = 136 | PILRA G/G n = 195 | PILRA A/A n = 27 | PILRA A/G n = 134 | PILRA G/G n = 193 | |
Age at blood collection, y, mean ± SD | 61.6 ± 5.1 | 61.3 ± 6.1 | 61.2 ± 5.2 | 59.4 ± 5.1 | 61.4 ± 5.7 | 61.3 ± 5.6 |
Age at diagnosis, y, mean ± SD | 71.9 ± 6.2 | 72.0 ± 6.2 | 71.1 ± 6.0 | |||
Sex, female, %, (n) | 81.0 (17) | 76.5 (104) | 74.4 (145) | 74.1 (20) | 73.9 (99) | 76.7 (148) |
APOE risk variants, % (n)a | 61.9 (13) | 61.5 (83) | 61.0 (119) | 44.4 (12) | 23.9 (32) | 21.9 (42) |
APOEε3/ε4 | 42.9 (9) | 45.2 (61) | 41.0 (80) | 37.0 (10) | 23.1 (31) | 20.3 (39) |
APOEε4/ε4 | 19.0 (4) | 16.3 (22) | 20.0 (39) | 7.4 (2) | 0.7 (1) | 1.6 (3) |
GM 3/17 | 38.1 (8) | 50.0 (66) | 46.4 (89) | 48.1 (13) | 48.5 (64) | 47.7 (92) |
GM 17/17, % (n) | 14.3 (3) | 20.5 (27) | 21.4 (41) | 25.9 (7) | 11.4 (15) | 8.3 (16) |
Anti-HSV-1 IgG + , % (n) | 90.5 (19) | 93.4 (127) | 90.3 (176) | 96.3 (26) | 89.6 (120) | 86.0 (166) |
Anti-HSV IgG levelsb,c | 106.4 ± 16.6 | 102.0 ± 23.2 | 102.3 ± 20.8 | 99.4 ± 21.2 | 99.8 ± 23.6 | 105.3 ± 20.7 |
Anti-HSV IgM + , % (n)c | 10.5 (2) | 8.7 (11) | 7.4 (13) | 0 (0) | 4.2 (5) | 7.2 (12) |
